Type 2 Diabetes Clinical Trial
Official title:
Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes
This pilot study will investigate the effect of Vitamin D supplementation in improving glucose control with patients with poorly controlled diabetes and concurrent Vitamin D deficiency.
Subject will undergo screening procedures, subject will have blood drawn from a vein in your
arm to measure subject's Vitamin D level (about 1 tablespoon).If the subject is eligible
based on the results of their blood work and the subject agrees to participate in this
study, the subject will return to the clinic to begin the study. There will be 4 study
visits every 2 months and phone interviews every 2 weeks during the 6 month study. In the
beginning (Visit 1) and end of the study (Visit 4), fasting blood samples will be collected
for analysis of fasting plasma glucose, %HbAlc (your long-term sugar control over a 3 month
period), calcium, insulin, and Vitamin D level. Urine samples will be collected to determine
urinary microalbumin-creatinine ratio (early protein loss in the kidneys). Blood pressure
will be measured three times with an automatic blood pressure machine. Height and weight
will be measured. A medical history questionnaire will be completed by subjects that will
include basic demographics, typical dietary intake, smoking and alcohol history, medical
history, as well as list of medications and over-the-counter supplements.
At Visit 1 the subject will be randomized (like the toss of a coin) to receive either a
sugar pill or a high dose Vitamin D medication, which the subject will take once a week for
8 weeks and then once a month for 4 months. The subject will have a 50:50 chance of
receiving one or the other pill. At Visit 2 and Visit 3, the subject will also get blood
work to analyze your calcium and Vitamin D level. At each clinic visit, the subject will
also have your blood sugar and high blood pressure managed closely by the study
investigators, both of who are doctors (one being a primary care doctor and another being an
endocrinology/diabetes doctor), according to a standardized preset flowchart.
This means that the doctors in this study will be controlling the subject's blood sugar and
blood pressure values closely and may be changing the subject's blood pressure and/or your
blood sugar medications during this study depending on what the subject's blood sugar and
blood pressure values are. The subject will be instructed not to have their own primary care
doctor or diabetes doctor adjust their diabetes or blood pressure as both will be managed
closely by the study doctors during the entire 6 month study period. The subject doctors'
will be sent a letter notifying of the subject's participation in the study and be
instructed not to adjust any of the subject's blood sugar or blood pressure medications
during the entire 6 month study as it will be done closely by the study doctors, as
clinically indicated. The subject's doctor will be sent letters after each study visit
detailing what changes were done, if any, to your blood sugar and blood pressure medication
regimen. The subject will be interviewed on the phone every 2 weeks to assess for any
medication adverse reactions and treatment compliance.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |